{"id":"62dfb5af-9564-4e97-8c4c-095a6c3af789","dataset":"sourcesCorporatePublication","time":34,"normalizedUIQL":null,"lastDatasetUpdate":"2019-02-16T00:12:36Z","PagedResults":{"total":151,"firstRow":1,"lastRow":140,"Result":[{"Field":[{"name":"sourceId","type":"string","value":"1419372"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 8K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":1},{"Field":[{"name":"sourceId","type":"string","value":"781965"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics website"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-04-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":2},{"Field":[{"name":"sourceId","type":"string","value":"505745"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10K: Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-03-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":3},{"Field":[{"name":"sourceId","type":"string","value":"1885960"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc: Form 8K"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 8K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-12-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":4},{"Field":[{"name":"sourceId","type":"string","value":"360311"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc S-1"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form S-1"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2000-03-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":5},{"Field":[{"name":"sourceId","type":"string","value":"1242093"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Company Worldwide Website"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-11-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":6},{"Field":[{"name":"sourceId","type":"string","value":"1608038"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics: Form 8-K"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 8K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-10-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":7},{"Field":[{"name":"sourceId","type":"string","value":"1309196"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics: Clinical pipeline"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-07-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":8},{"Field":[{"name":"sourceId","type":"string","value":"781989"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics 10-K: 2006"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-02-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":9},{"Field":[{"name":"sourceId","type":"string","value":"781991"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-K: Pain Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-02-24T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":10},{"Field":[{"name":"sourceId","type":"string","value":"1268079"},{"name":"corporatePublicationTitle","type":"string","value":"The American Academy of Pain Medicine: AAPM Facts and Figures on Pain"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"The American Academy of Pain Medicine"}],"pos":11},{"Field":[{"name":"sourceId","type":"string","value":"505767"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 2002: Pain Therapeutics, Inc"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":12},{"Field":[{"name":"sourceId","type":"string","value":"476541"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc - 2003 conference call"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":13},{"Field":[{"name":"sourceId","type":"string","value":"922396"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-K 2007 - Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-02-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":14},{"Field":[{"name":"sourceId","type":"string","value":"781993"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-k: Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-03-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":15},{"Field":[{"name":"sourceId","type":"string","value":"625372"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc: Annual report 2004"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":16},{"Field":[{"name":"sourceId","type":"string","value":"1742991"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-K 2015 - Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-03-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":17},{"Field":[{"name":"sourceId","type":"string","value":"982143"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics: pipeline, factor IX replacement"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-02-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":18},{"Field":[{"name":"sourceId","type":"string","value":"922398"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 2007 - Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":19},{"Field":[{"name":"sourceId","type":"string","value":"2011331"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-K 2017 - Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2018-02-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":20},{"Field":[{"name":"sourceId","type":"string","value":"1907552"},{"name":"corporatePublicationTitle","type":"string","value":"Form 10-K 2016 - Pain Therapeutics Inc"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2017-03-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":21},{"Field":[{"name":"sourceId","type":"string","value":"1012948"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc: Annual Report for the year ended 31 December 2008"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":22},{"Field":[{"name":"sourceId","type":"string","value":"1012944"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc: Form 10-K for the year ended 31 December 2008"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-02-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":23},{"Field":[{"name":"sourceId","type":"string","value":"625373"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Therapeutics Inc: Form 10K for the year ended 31 December 2004"},{"name":"corporatePublicationType","type":"string","value":"Securities and Exchange Commission Form 10-K"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-02-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pain Therapeutics Inc"}],"pos":24},{"Field":[{"name":"sourceId","type":"string","value":"1260586"},{"name":"corporatePublicationTitle","type":"string","value":"International Association for the Study of Pain: IASP Taxonomy"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"International Association for the Study of Pain"}],"pos":25},{"Field":[{"name":"sourceId","type":"string","value":"1072598"},{"name":"corporatePublicationTitle","type":"string","value":"Pain Relief / Analgesia - Healthcare Professionals"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Medical Developments International Ltd"}],"pos":26},{"Field":[{"name":"sourceId","type":"string","value":"979172"},{"name":"corporatePublicationTitle","type":"string","value":"Pain therapy"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-01-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Grunenthal GmbH"}],"pos":27},{"Field":[{"name":"sourceId","type":"string","value":"500881"},{"name":"corporatePublicationTitle","type":"string","value":"Drug discovery: Therapeutic Focus, Chronic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Amedis Pharmaceuticals Ltd"}],"pos":28},{"Field":[{"name":"sourceId","type":"string","value":"207756"},{"name":"corporatePublicationTitle","type":"string","value":"Product Profile: DepoMorphine post-surgical acute pain management"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1996-05-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"DepoTech Corp"}],"pos":29},{"Field":[{"name":"sourceId","type":"string","value":"1313897"},{"name":"corporatePublicationTitle","type":"string","value":"Assessment and Management of Acute Pain (6th Edition)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Institute for Clinical Systems Improvement"}],"pos":30},{"Field":[{"name":"sourceId","type":"string","value":"406336"},{"name":"corporatePublicationTitle","type":"string","value":"Corporate profile: Topical pain therapy for the treatment chronic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-04-19T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Epitome Pharmaceuticals Ltd"}],"pos":31},{"Field":[{"name":"sourceId","type":"string","value":"612174"},{"name":"corporatePublicationTitle","type":"string","value":"Pain and inflammation therapeutics - a non-narcotic agent for treating acute and chronic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-07-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Microbia Inc"}],"pos":32},{"Field":[{"name":"sourceId","type":"string","value":"1274832"},{"name":"corporatePublicationTitle","type":"string","value":"Fentanyl patches (Durogesic) for chronic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-06-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Australian Government Department of Health and Ageing"}],"pos":33},{"Field":[{"name":"sourceId","type":"string","value":"531000"},{"name":"corporatePublicationTitle","type":"string","value":"Biosciences Division: Pain/analgesia: Basic research"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-04-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SRI International"}],"pos":34},{"Field":[{"name":"sourceId","type":"string","value":"474063"},{"name":"corporatePublicationTitle","type":"string","value":"Acute and Chronic Pain: RI-624"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-12-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Rinat Neuroscience Corp"}],"pos":35},{"Field":[{"name":"sourceId","type":"string","value":"1738619"},{"name":"corporatePublicationTitle","type":"string","value":"Essential Pain Pharmacology"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-02-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cambridge Medicine"}],"pos":36},{"Field":[{"name":"sourceId","type":"string","value":"501059"},{"name":"corporatePublicationTitle","type":"string","value":"Products - Pain - Migraine - SRSS-023"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sirus Pharmaceuticals Ltd"}],"pos":37},{"Field":[{"name":"sourceId","type":"string","value":"784427"},{"name":"corporatePublicationTitle","type":"string","value":"MediVas: Applications: Pain Management"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-04-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"MediVas LLC"}],"pos":38},{"Field":[{"name":"sourceId","type":"string","value":"1091181"},{"name":"corporatePublicationTitle","type":"string","value":"NOLabs Ab: Diabetic pain relief"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-01-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NOLabs Ab"}],"pos":39},{"Field":[{"name":"sourceId","type":"string","value":"907883"},{"name":"corporatePublicationTitle","type":"string","value":"M6G â€“ post-operative pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-05-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CeNeS Pharmaceuticals Inc"}],"pos":40},{"Field":[{"name":"sourceId","type":"string","value":"480162"},{"name":"corporatePublicationTitle","type":"string","value":"Ardent: Moderate-to-severe pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-02-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ardent Pharmaceuticals Inc"}],"pos":41},{"Field":[{"name":"sourceId","type":"string","value":"970073"},{"name":"corporatePublicationTitle","type":"string","value":"company website pain research pipeline"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Abbott Laboratories"}],"pos":42},{"Field":[{"name":"sourceId","type":"string","value":"500889"},{"name":"corporatePublicationTitle","type":"string","value":"Products - Pain - Neuropathic - SRSC-355"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sirus Pharmaceuticals Ltd"}],"pos":43},{"Field":[{"name":"sourceId","type":"string","value":"455033"},{"name":"corporatePublicationTitle","type":"string","value":"Sedation and Pain Relief"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orion Pharma"}],"pos":44},{"Field":[{"name":"sourceId","type":"string","value":"500887"},{"name":"corporatePublicationTitle","type":"string","value":"Products - Pain - Breakthrough - SRSS-001"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sirus Pharmaceuticals Ltd"}],"pos":45},{"Field":[{"name":"sourceId","type":"string","value":"1063841"},{"name":"corporatePublicationTitle","type":"string","value":"Pain in Europe: A report"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-10-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PainEurope.com"}],"pos":46},{"Field":[{"name":"sourceId","type":"string","value":"501058"},{"name":"corporatePublicationTitle","type":"string","value":"Products - Pain - Acute - SRSS-016"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Sirus Pharmaceuticals Ltd"}],"pos":47},{"Field":[{"name":"sourceId","type":"string","value":"1930623"},{"name":"corporatePublicationTitle","type":"string","value":"Rapid, Reliable Pain Relief"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-11-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Klaria Pharma Holding Ab"}],"pos":48},{"Field":[{"name":"sourceId","type":"string","value":"876237"},{"name":"corporatePublicationTitle","type":"string","value":"Product Pipeline: TC-2696 pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-02-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Targacept Inc"}],"pos":49},{"Field":[{"name":"sourceId","type":"string","value":"590572"},{"name":"corporatePublicationTitle","type":"string","value":"Home - Programs - Neuropathic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2005-03-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ACADIA Pharmaceuticals Inc"}],"pos":50},{"Field":[{"name":"sourceId","type":"string","value":"968756"},{"name":"corporatePublicationTitle","type":"string","value":"Abbott pain research pipeline"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Abbott Laboratories"}],"pos":51},{"Field":[{"name":"sourceId","type":"string","value":"1565018"},{"name":"corporatePublicationTitle","type":"string","value":"Company communication - Pain research"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-05-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"AbbVie Inc"}],"pos":52},{"Field":[{"name":"sourceId","type":"string","value":"1025895"},{"name":"corporatePublicationTitle","type":"string","value":"Glial Cellsâ€”A New Target for Chronic Pain Treatment"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Avigen Inc"}],"pos":53},{"Field":[{"name":"sourceId","type":"string","value":"1274333"},{"name":"corporatePublicationTitle","type":"string","value":"KINDOLOR - A new molecular entity for treating chronic pain and cancer"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-03-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Lohocla Research Corp"}],"pos":54},{"Field":[{"name":"sourceId","type":"string","value":"277409"},{"name":"corporatePublicationTitle","type":"string","value":"DepoTech Corp product profile - DepoMorphine - post-surgical acute pain management"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-02-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"DepoTech Corp"}],"pos":55},{"Field":[{"name":"sourceId","type":"string","value":"441966"},{"name":"corporatePublicationTitle","type":"string","value":"ZeP-3: a synthetic drug of natural origin for chronic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Shulov Institute for Science Ltd"}],"pos":56},{"Field":[{"name":"sourceId","type":"string","value":"666890"},{"name":"corporatePublicationTitle","type":"string","value":"Sufentanil TDS: A Licensing Opportunity for the Chronic Pain Market"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-01-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Labtec GmbH"}],"pos":57},{"Field":[{"name":"sourceId","type":"string","value":"944118"},{"name":"corporatePublicationTitle","type":"string","value":"Rapinyl /Abstral - treatment of acute pain in cancer patients"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-09-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orexo AB"}],"pos":58},{"Field":[{"name":"sourceId","type":"string","value":"1161303"},{"name":"corporatePublicationTitle","type":"string","value":"Cancer pain treatment, \"WandyuroÂ  Â® Â Patch \"Gets Approval"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-01-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Janssen Pharmaceutical Co., Ltd."}],"pos":59},{"Field":[{"name":"sourceId","type":"string","value":"1363123"},{"name":"corporatePublicationTitle","type":"string","value":"Technology offer: Adjuvant for improved regional pain management"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-01-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Bayerische Patentallianz GmbH"}],"pos":60},{"Field":[{"name":"sourceId","type":"string","value":"462649"},{"name":"corporatePublicationTitle","type":"string","value":"Making waves with solutions in pain management"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"International Wex Technologies Inc"}],"pos":61},{"Field":[{"name":"sourceId","type":"string","value":"1012109"},{"name":"corporatePublicationTitle","type":"string","value":"Prolonged release of Lidocaine for pain relief"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-05-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Uppsala University"}],"pos":62},{"Field":[{"name":"sourceId","type":"string","value":"453915"},{"name":"corporatePublicationTitle","type":"string","value":"Enhance.L: Pain relief for OBGYN procedures"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-06-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Enhance Pharmaceuticals Inc"}],"pos":63},{"Field":[{"name":"sourceId","type":"string","value":"962385"},{"name":"corporatePublicationTitle","type":"string","value":"Phosphagenics Ltd: Delivering Pain Drugs Topically and Systemically"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-10-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Phosphagenics Ltd"}],"pos":64},{"Field":[{"name":"sourceId","type":"string","value":"1559893"},{"name":"corporatePublicationTitle","type":"string","value":"Pain indication update for ALO-02 and Remoxy"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-05-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pfizer Inc"}],"pos":65},{"Field":[{"name":"sourceId","type":"string","value":"867257"},{"name":"corporatePublicationTitle","type":"string","value":"Enhance pain management using endothelin receptor antagonists"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-01-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Illinois"}],"pos":66},{"Field":[{"name":"sourceId","type":"string","value":"1204544"},{"name":"corporatePublicationTitle","type":"string","value":"Xefo Rapid (lornoxicam) â€“ for fast pain relief"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":67},{"Field":[{"name":"sourceId","type":"string","value":"1273841"},{"name":"corporatePublicationTitle","type":"string","value":"Therapeutic Class Review - Pain - Short-actign Opioids"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-04-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":68},{"Field":[{"name":"sourceId","type":"string","value":"1211590"},{"name":"corporatePublicationTitle","type":"string","value":"TLI-0326: Oral Treatment of Diabetic Neuropathy Pain"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-07-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Trinity Laboratories Inc"}],"pos":69},{"Field":[{"name":"sourceId","type":"string","value":"1275346"},{"name":"corporatePublicationTitle","type":"string","value":"Therapeutic Class ReviewÂ Pain - Long-Acting Opioids: Embeda"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-04-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":70},{"Field":[{"name":"sourceId","type":"string","value":"435316"},{"name":"corporatePublicationTitle","type":"string","value":"Neurology CEDD disease area strategy/ Pain"},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-11-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"GlaxoSmithKline plc"}],"pos":71},{"Field":[{"name":"sourceId","type":"string","value":"1037064"},{"name":"corporatePublicationTitle","type":"string","value":"Abstral-treatment of breakthough cancer pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-08-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Orexo"}],"pos":72},{"Field":[{"name":"sourceId","type":"string","value":"851078"},{"name":"corporatePublicationTitle","type":"string","value":"CNS: Pain Program Fact Sheet: PLX-5568"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-10-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Plexxikon Inc"}],"pos":73},{"Field":[{"name":"sourceId","type":"string","value":"792923"},{"name":"corporatePublicationTitle","type":"string","value":"Targacept: Product pipeline: TC-6499 pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Targacept Inc"}],"pos":74},{"Field":[{"name":"sourceId","type":"string","value":"1471098"},{"name":"corporatePublicationTitle","type":"string","value":"Breakthrough Therapies for Neuropathic Pain and Neurological Disorders"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-04-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Colorado Technology Transfer Office"}],"pos":75},{"Field":[{"name":"sourceId","type":"string","value":"1263741"},{"name":"corporatePublicationTitle","type":"string","value":"Xen2174-A new class of pain therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-02-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Xenome Ltd"}],"pos":76},{"Field":[{"name":"sourceId","type":"string","value":"399819"},{"name":"corporatePublicationTitle","type":"string","value":"Annual report: chairman's statement. Analgesia: Devacade and Colycade - for enhancing the pain relief produced by morphine"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-02-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ML Laboratories plc"}],"pos":77},{"Field":[{"name":"sourceId","type":"string","value":"1256481"},{"name":"corporatePublicationTitle","type":"string","value":"A pilot study on the effect of ARA290 on pain and pain responses and retinal edema in patients with diabetes mellitus and neuropathic pain; EudraCT Number: 2010-021518-4"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-02-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Araim Pharmaceuticals Inc"}],"pos":78},{"Field":[{"name":"sourceId","type":"string","value":"1895559"},{"name":"corporatePublicationTitle","type":"string","value":"AnestaGelâ€“P Provides Greater Analgesia in a Rat Model of PostOperative Incisional Pain with Mechanical Allodynia than Exparel at 24 and 48 Hours"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-06-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Taylor W, Sipple DP, Sinicropi SM"}],"pos":79},{"Field":[{"name":"sourceId","type":"string","value":"1461524"},{"name":"corporatePublicationTitle","type":"string","value":"A Phase II Novel Therapeutic Approach for Treating Pain Approach for Treating Pain, Multiple Multiple Sclerosis, or Drug Addiction"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":80},{"Field":[{"name":"sourceId","type":"string","value":"1365878"},{"name":"corporatePublicationTitle","type":"string","value":"PHE377: A novel clinical-stage TRPV1 antagonist devoid of â€œclassâ€? side effects for the treatment of chronic pain syndromes"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-02-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PharmEste SRL"}],"pos":81},{"Field":[{"name":"sourceId","type":"string","value":"831368"},{"name":"corporatePublicationTitle","type":"string","value":"BioCentury, The Bernstein Report Emerging Company Profile Solace: Comfort in (Pain) Research"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-07-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Solace Pharmaceuticals"}],"pos":82},{"Field":[{"name":"sourceId","type":"string","value":"505307"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline - vanilloid receptor 1 antagonists (pain), Purdue Pharma"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-09-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Purdue Pharma LP"}],"pos":83},{"Field":[{"name":"sourceId","type":"string","value":"665802"},{"name":"corporatePublicationTitle","type":"string","value":"KD7040 - topical pain product. Inducible nitric oxide synthase (iNOS) inhibitor 2Q2006"},{"name":"corporatePublicationType","type":"string","value":"Company Newsletter"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-05-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Kalypsys Inc"}],"pos":84},{"Field":[{"name":"sourceId","type":"string","value":"1268281"},{"name":"corporatePublicationTitle","type":"string","value":"Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Institute of Medicine of the National Academies"}],"pos":85},{"Field":[{"name":"sourceId","type":"string","value":"1096851"},{"name":"corporatePublicationTitle","type":"string","value":"Designing systemically active galanin analogs for the treatment of epilepsy and pain"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NeuroAdjuvants Inc"}],"pos":86},{"Field":[{"name":"sourceId","type":"string","value":"1609911"},{"name":"corporatePublicationTitle","type":"string","value":"GDC-0276 and Other Selective Inhibitors of NaV1.7 for the Treatment of Pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-11-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Xenon Pharmaceuticals Inc"}],"pos":87},{"Field":[{"name":"sourceId","type":"string","value":"460461"},{"name":"corporatePublicationTitle","type":"string","value":"Information for shareholders on the progress of the Canadian cancer pain trial"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2002-03-27T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"International Wex Technologies Inc"}],"pos":88},{"Field":[{"name":"sourceId","type":"string","value":"755450"},{"name":"corporatePublicationTitle","type":"string","value":"Horizon Therapeutics: Novel therapeis for mild-to-moderate pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-01-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Horizon Therapeutics Inc"}],"pos":89},{"Field":[{"name":"sourceId","type":"string","value":"1272464"},{"name":"corporatePublicationTitle","type":"string","value":"Technology offer: Use of beta-adrenergic receptor agonists for treatment of neuropathic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-03-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Conectus Alsace"}],"pos":90},{"Field":[{"name":"sourceId","type":"string","value":"1310203"},{"name":"corporatePublicationTitle","type":"string","value":"UP-069: Prevention and treatment of pain in diabetes mellitus patients"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-07-23T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Heidelberg"}],"pos":91},{"Field":[{"name":"sourceId","type":"string","value":"494391"},{"name":"corporatePublicationTitle","type":"string","value":"A new option for cancer patients: Advanced pain management with transdermal buprenorphine (Transtec)"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2003-06-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Gruenenthal GmbH"}],"pos":92},{"Field":[{"name":"sourceId","type":"string","value":"1312531"},{"name":"corporatePublicationTitle","type":"string","value":"Xefo as an adjunct agent in post-operative pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2012-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Takeda Pharmaceutical Co Ltd"}],"pos":93},{"Field":[{"name":"sourceId","type":"string","value":"643947"},{"name":"corporatePublicationTitle","type":"string","value":"Spinifex: Developing novel solutions for the treatment of pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-01-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Spinifex Pharmaceuticals Pty Ltd"}],"pos":94},{"Field":[{"name":"sourceId","type":"string","value":"920427"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development update: TRPV3 receptor antagonists (pain/osteoarthritis), Glenmark"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-06-26T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Glenmark Pharmaceuticals Ltd"}],"pos":95},{"Field":[{"name":"sourceId","type":"string","value":"1363116"},{"name":"corporatePublicationTitle","type":"string","value":"FMP website; Technology offer TO 08-00085: Peptide for improved pain management"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-01-25T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Leibniz-Institut fur Molekulare Pharmakologie"}],"pos":96},{"Field":[{"name":"sourceId","type":"string","value":"1209378"},{"name":"corporatePublicationTitle","type":"string","value":"A new paradigm in pain treatment- Project APN601 (DREAM)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-07-20T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Apeiron Biologics GmbH"}],"pos":97},{"Field":[{"name":"sourceId","type":"string","value":"1208016"},{"name":"corporatePublicationTitle","type":"string","value":"A new paradigm in pain treatment-Project APN601 (DREAM)"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-07-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Apeiron Biologics GmbH"}],"pos":98},{"Field":[{"name":"sourceId","type":"string","value":"1041160"},{"name":"corporatePublicationTitle","type":"string","value":"Archimedes Announces US Filing of NasalFentÂ®for the treatment of Breakthrough Cancer Pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-09-11T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Archimedes Pharma"}],"pos":99},{"Field":[{"name":"sourceId","type":"string","value":"923876"},{"name":"corporatePublicationTitle","type":"string","value":"Anesiva: Annual report 2007 \"Changing the face of pain\""},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-03-14T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Anesiva Inc"}],"pos":100},{"Field":[{"name":"sourceId","type":"string","value":"1215629"},{"name":"corporatePublicationTitle","type":"string","value":"[Drug development update]: therapeutic program (inflammation/autoimmune diseases/pain), SEEK"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-08-12T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"SEEK"}],"pos":101},{"Field":[{"name":"sourceId","type":"string","value":"675243"},{"name":"corporatePublicationTitle","type":"string","value":"Anesiva Inc: Annual report 2005 (labelled as \"Corgentech\") - \"Building a Pain Management Franchise\""},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-03-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Anesiva Inc"}],"pos":102},{"Field":[{"name":"sourceId","type":"string","value":"955145"},{"name":"corporatePublicationTitle","type":"string","value":"Clinical Observation on the Effect of Kanglaite Injection in the Treatment of Cancerous Pain"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-10-13T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Luo, Yao, Wang"}],"pos":103},{"Field":[{"name":"sourceId","type":"string","value":"180514"},{"name":"corporatePublicationTitle","type":"string","value":"Oral analgesic combination for patients with moderate to severe pain."},{"name":"corporatePublicationType","type":"string","value":"Company Brochure"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1995-03-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"British Technology Group Ltd"}],"pos":104},{"Field":[{"name":"sourceId","type":"string","value":"398273"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: ion channel modulators for epilepsy and pain therapy"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-02-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"ICAgen Inc"}],"pos":105},{"Field":[{"name":"sourceId","type":"string","value":"1441157"},{"name":"corporatePublicationTitle","type":"string","value":"NEO6860: Vanilloid receptor antagonists for the treatment of osteoarthritis, neuropathic and visceral pain"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-04-18T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NEOMED Institute"}],"pos":106},{"Field":[{"name":"sourceId","type":"string","value":"1382419"},{"name":"corporatePublicationTitle","type":"string","value":"EP4 Receptor Antagonist for Chronic Inflammatory Pain; Worldwide Partnering Opportunity"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"RaQualia Pharma Inc"}],"pos":107},{"Field":[{"name":"sourceId","type":"string","value":"1072323"},{"name":"corporatePublicationTitle","type":"string","value":"NOVEL SODIUM CHANNEL BLOCKERS FOR THE TREATMENT OF NEUROPATHIC PAIN"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-02-02T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Neurosciences Victoria Ltd"}],"pos":108},{"Field":[{"name":"sourceId","type":"string","value":"1249034"},{"name":"corporatePublicationTitle","type":"string","value":"Lipopharma: LPA181 in Spinal Cord Injury &amp; neuropathic pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-12-15T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Lipopharma Therapeutics SL"}],"pos":109},{"Field":[{"name":"sourceId","type":"string","value":"1709074"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: baclofen (Gablofen); Treatment of complex regional pain syndrome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-10-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":110},{"Field":[{"name":"sourceId","type":"string","value":"536728"},{"name":"corporatePublicationTitle","type":"string","value":"Microbia Inc R&amp;D Pipeline: Pain and Inflammation Therapeutics"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2004-05-05T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Microbia Inc"}],"pos":111},{"Field":[{"name":"sourceId","type":"string","value":"1709890"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: baclofen (Gablofen); Treatment of complex regional pain syndrome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-10-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":112},{"Field":[{"name":"sourceId","type":"string","value":"789119"},{"name":"corporatePublicationTitle","type":"string","value":"Antibe Therapeutics Inc: Product Platform and Pipeline: ATB-346: Acute and Chronic Joint Pain"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-05-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Antibe Therapeutics Inc"}],"pos":113},{"Field":[{"name":"sourceId","type":"string","value":"1273451"},{"name":"corporatePublicationTitle","type":"string","value":"Novel oramucosal (Abstral, Effentora) and nasal (Instanyl) fentanyl for breakthrough pain associated with cancer"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-09-30T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"NHS North East Treatment Advisory Group"}],"pos":114},{"Field":[{"name":"sourceId","type":"string","value":"1031773"},{"name":"corporatePublicationTitle","type":"string","value":"Pegylation Of Interleukin-10 To Enhance Delivery To The Central Nervous System And Therapeutic Efficacy For Neuropathic Pain"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2007-11-08T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"University of Colorado System"}],"pos":115},{"Field":[{"name":"sourceId","type":"string","value":"424770"},{"name":"corporatePublicationTitle","type":"string","value":"AstraZeneca research: cardiovascular, central nervous system, gastrointestinal, infection, oncology, pain control &amp; anaesthesia and respiratory"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-10-09T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"AstraZeneca plc"}],"pos":116},{"Field":[{"name":"sourceId","type":"string","value":"1192276"},{"name":"corporatePublicationTitle","type":"string","value":"Extended-release multivesicular liposome bupivacaine (EXPAREL) is superior to placebo for post-hemorrhoidectomy pain reduction"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2011-05-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pacira Pharmaceuticals Inc"}],"pos":117},{"Field":[{"name":"sourceId","type":"string","value":"1774357"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: hydromorphone hydrochloride (intrathecal infusion); Â Treatment of complex regional pain syndrome"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-06-16T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":118},{"Field":[{"name":"sourceId","type":"string","value":"1193896"},{"name":"corporatePublicationTitle","type":"string","value":"The American College of Obstetricians and Gynecologists (ACOG): Pain Management of Endometriosis - Conservative approach is first-line treatment"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-06-22T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"http://www.acog.org/from_home/publications/press_releases/nr06-22-10-3.cfm"}],"pos":119},{"Field":[{"name":"sourceId","type":"string","value":"446138"},{"name":"corporatePublicationTitle","type":"string","value":"Annual Report 2001: Ono Pharmaceutical Co Ltd - Dedicated to Man's fight against disease and pain"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2001-06-28T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ono Pharmaceutical Co Ltd"}],"pos":120},{"Field":[{"name":"sourceId","type":"string","value":"1148298"},{"name":"corporatePublicationTitle","type":"string","value":"To provide patients with therapeutics that address todayâ€™s unmet medical needs in pain and inflammation"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-05-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Cerimon Pharmaceuticals Inc"}],"pos":121},{"Field":[{"name":"sourceId","type":"string","value":"1209320"},{"name":"corporatePublicationTitle","type":"string","value":"PF0713 Produced Rapid Induction of General Anesthesia without Injection Pain in a Phase 1 Study"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2009-10-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"PharmacoFore Inc"}],"pos":122},{"Field":[{"name":"sourceId","type":"string","value":"241305"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Dopamine D1 agonists, CeNeS, Alzheimers therapeutics, CeNeS, pain therapeutics, CeNeS/Kings College"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1997-04-04T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CeNeS Limited"}],"pos":123},{"Field":[{"name":"sourceId","type":"string","value":"1421605"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: zoledronic acid; Treatment of complex regional pain syndrome (CRPS)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-05-06T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":124},{"Field":[{"name":"sourceId","type":"string","value":"1770451"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: bupivacaine hydrochloride;Â treatment of pain associated with postherpetic neuralgia"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-05-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":125},{"Field":[{"name":"sourceId","type":"string","value":"1139094"},{"name":"corporatePublicationTitle","type":"string","value":"ARRY-797, a Small Molecule p38Î± Inhibitor, Has a Good Safety Profile and Provides Pain Relief in Clinical Studies"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-08-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Array BioPharma Inc"}],"pos":126},{"Field":[{"name":"sourceId","type":"string","value":"1102174"},{"name":"corporatePublicationTitle","type":"string","value":"Society for Ambulatory Anesthesia Annual Meeting: Intranasal Ketorolac (ROX-888) for Postoperative Pain: A Phase 3, Double-Blind, Randomized Study"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Singla N, Singla S, Minkowitz H, Brown C, Moodie J"}],"pos":127},{"Field":[{"name":"sourceId","type":"string","value":"1543089"},{"name":"corporatePublicationTitle","type":"string","value":"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated with HIV Neuropathy"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":128},{"Field":[{"name":"sourceId","type":"string","value":"1530910"},{"name":"corporatePublicationTitle","type":"string","value":"Flexion: New Paradigms for the Treatment of Pain - Presentation at the Cowen and Company 2014 Annual Health Care Conference"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-03-03T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Flexion Therapeutics"}],"pos":129},{"Field":[{"name":"sourceId","type":"string","value":"2020459"},{"name":"corporatePublicationTitle","type":"string","value":"Phase 2 Studies of HTX-011 in the Management of Post-Operative Pain - Positive Top -Line Results across Bunion and Hernia Studies"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2016-08-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Heron Therapeutics Inc"}],"pos":130},{"Field":[{"name":"sourceId","type":"string","value":"1482891"},{"name":"corporatePublicationTitle","type":"string","value":"Intravenous Paracetamol as an Adjunct to Patient-Controlled Epidural Analgesia With Levobupivacaine and Fentanyl in Labour: A Randomized, Controlled Study"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2013-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":131},{"Field":[{"name":"sourceId","type":"string","value":"1104282"},{"name":"corporatePublicationTitle","type":"string","value":"Society for Biological Sciences Conference: Identification of Novel Selective CB2 Agonists for Pain Treatment through an HTS Campaign with chAMPion Technology"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Axxam SpA"}],"pos":132},{"Field":[{"name":"sourceId","type":"string","value":"1724369"},{"name":"corporatePublicationTitle","type":"string","value":"Depomed Inc Corporate Call to Acquires U.S. Rights to Late-Stage, First-in-Class Pain Product from Grunenthal"},{"name":"corporatePublicationType","type":"string","value":"Company Presentation"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-11-17T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Depomed Inc"}],"pos":133},{"Field":[{"name":"sourceId","type":"string","value":"290425"},{"name":"corporatePublicationTitle","type":"string","value":"Drug development pipeline: Parkinsons therapeutics, CeNeS/Kings College, Alzheimers therapeutics, CeNeS, CEE-04-421, pain therapeutics, CeNeS/Kings College"},{"name":"corporatePublicationType","type":"string","value":"Company Communication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"1998-10-07T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"CeNeS Ltd"}],"pos":134},{"Field":[{"name":"sourceId","type":"string","value":"1142479"},{"name":"corporatePublicationTitle","type":"string","value":"Azur Pharma Announces the Closing of the Acquisition of PRIALT CNS/Pain Specialty Infrastructure - - - End-User Sales of $20 Million in 2009"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2010-05-10T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Azur Pharma"}],"pos":135},{"Field":[{"name":"sourceId","type":"string","value":"1652817"},{"name":"corporatePublicationTitle","type":"string","value":"FDA Orphan Drug Designations and Approvals: zoledronate D,L-lysine monohydrate (ZLM); Treatment of complex regional pain syndrome (CRPS)"},{"name":"corporatePublicationType","type":"string","value":"Company World Wide Web site"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2015-04-21T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Food and Drug Administration"}],"pos":136},{"Field":[{"name":"sourceId","type":"string","value":"693128"},{"name":"corporatePublicationTitle","type":"string","value":"Ono Pharmaceutical Co Ltd: Annual report 2006 \"Dedicated to Man's Fight against Disease and Pain\" Year ended March 31, 2006"},{"name":"corporatePublicationType","type":"string","value":"Annual Report"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2006-06-29T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Ono Pharmaceutical Co Ltd"}],"pos":137},{"Field":[{"name":"sourceId","type":"string","value":"1574744"},{"name":"corporatePublicationTitle","type":"string","value":"A single-blind two-part study to rechallenge with subcutaneous GR43175C, patients who had previously experienced an adverse event involving discomfort or pain in the chest following GR43175C administration"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":138},{"Field":[{"name":"sourceId","type":"string","value":"990738"},{"name":"corporatePublicationTitle","type":"string","value":"A3471107: A multicenter, open label trial to evaluate analgesic effect of intravenous and subsequent oral therapy with parecoxib/valdecoxib (Bextra IM/IV - Bextra) 40 mg for treatment of post laparoscopic surgery pain"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2008-04-01T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":"Pfizer Inc"}],"pos":139},{"Field":[{"name":"sourceId","type":"string","value":"1574982"},{"name":"corporatePublicationTitle","type":"string","value":"A Multicenter, randomized, double-blind, parallel-group study examining the effect of fluticasone propionate aqueous nasal spray 200mcg QD in subjects with sinus pain and pressure associated with nasal congestion due to allergic rhinitis"},{"name":"corporatePublicationType","type":"string","value":"Company Publication"},{"name":"corporatePublicationDatePublication","type":"datetime","value":"2014-12-31T00:00:00Z"},{"name":"corporatePublicationCompanyOwnerName","type":"string","value":null}],"pos":140}]},"DatasetCounts":[],"HitTerms":{"Term":[{"value":"pain"}],"Synonym":[{"value":"acute pain"},{"value":"acute pain indication"},{"value":"analgesia"},{"value":"chronic pain"},{"value":"chronic pain indication"},{"value":"lesion pain"}]},"serviceExecutionTime":44}